You are here

  • Home
  • Archive
  • Volume 80, Issue 4
  • Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area

Article Text

Article menu
Download PDFPDF
Letter
Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area
  1. Rim Bourguiba1,
  2. Marion Delplanque1,
  3. Caroline Vinit2,
  4. Felix Ackermann3,
  5. Léa Savey1,
  6. Gilles Grateau1,
  7. Veronique Hentgen2,
  8. Sophie Georgin-lavialle1
  1. 1 Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
  2. 2 General pediatry department, Versaille hospital, André-Mignot, General pediatry department, National reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), versailles, France
  3. 3 Department of Internal Medicine, Hopital Foch, Sursennes, France
  1. Correspondence to Professor Sophie Georgin-lavialle, Tenon Hospital, Internal Medicine, AP-HP, Paris 75020, France; sophie.georgin-lavialle{at}aphp.fr

http://dx.doi.org/10.1136/annrheumdis-2020-218707

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The novel COVID-19 pandemic caused by SARS-CoV-2 is responsible for many deaths worldwide. Severe or life-threatening disease induce an exaggerated inflammatory response known as the ‘cytokine storm’, raising the question of the susceptibility and severity of SARS-CoV-2 infection in patients displaying innate immunity disorders such as familial Mediterranean fever (FMF). Furthermore, FMF patients take a long-term therapy with colchicine, which has been tested in SARS-CoV-2-infected patients with conflicting results.1

    To tackle this question, we conducted a survey on SARS-CoV-2 infection in FMF patients followed in Paris area. In that meantime, the official French rate of infection in Paris area was 11% of the whole population.2 FMF patients were identified from the juvenile inflammatory rheumatism (JIR) cohort, an international multicenter data repository and consented to the study. For the purpose of the study, we included only patients fulfilling the international FMF criteria, with a genetic confirmed FMF diagnosis,3 and followed up in the French national autoinflammatory centre in Paris area.

    Identified patients (n=627) were invited to answer a short questionnaire in consultation by phone or email about a possible SARS-CoV-2 infection during the time span …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Twitter @Rimbourguiba1, @SophieGeorgin

    • RB and MD contributed equally.

    • Correction notice This article has been corrected since it published Online First. The author, Dr Ackermann, has been added to the author list.

    • Contributors All Authors contributed in writing the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval This observational study was based on data extracted from the Juvenile inflammatory Rheumatism (JIR) cohort, an international multicenter data repository established by the National Commission on Informatics and Liberty.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.